Você pesquisou por y - Revista Brasileira de Ginecologia e Obstetrícia
You searched for:"Walquíria Quida Salles Pereira Primo"
We found (9) results for your search.
, , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2023;45(5):293-296
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2023;45(5):293-296
, , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2023;45(3):161-167
, , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2023;45(3):161-167
, , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2023;45(1):01-02
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2023;45(1):01-02
, , , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(2):202-209
, , , , , , , , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(2):202-209
, , , , , , , , , , , , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2021;43(8):638-643
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2021;43(8):638-643
, , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2021;43(1):1-2
, , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2021;43(1):1-2
, , , , , , , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2020;42(7):415-419
, , , , , , , , , It is estimated that around 28 million surgeries will be postponed or canceled worldwide as a result of this pandemic, causing a delay in the diagnosis and treatment of more than 2 million cancer cases. In Brazil, both the National Health Agency (ANS) and National Health Surveillance Agency (ANVISA) advised the postponement of elective and non-essential surgeries, causing a considerable impact on the number of surgical procedures that decreased by 33.4% in this period. However, some women need treatment for various gynecological diseases that cannot be postponed. The purpose of this article is to present recommendations on surgical treatment during the COVID-19 pandemic.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2020;42(7):415-419
, , , , , , , , , It is estimated that around 28 million surgeries will be postponed or canceled worldwide as a result of this pandemic, causing a delay in the diagnosis and treatment of more than 2 million cancer cases. In Brazil, both the National Health Agency (ANS) and National Health Surveillance Agency (ANVISA) advised the postponement of elective and non-essential surgeries, causing a considerable impact on the number of surgical procedures that decreased by 33.4% in this period. However, some women need treatment for various gynecological diseases that cannot be postponed. The purpose of this article is to present recommendations on surgical treatment during the COVID-19 pandemic.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2018;40(6):360-368
Evidence-based clinical guidelines ensure best practice protocols are available in health care. There is a widespread use of human papillomavirus deoxyribonucleic acid (HPVDNA) tests in Brazil, regardless of the lack of official guidelines. On behalf of the Brazilian Association for the Lower Genital Tract Pathology and Colposcopy (ABPTGIC, in the Portuguese acronym), a team of reviewers searched for published evidence and developed a set of recommendations for the use of HPV-DNA tests in cervical cancer screening in Brazil. The product of this process was debated and consensus was sought by the participants. One concern of the authors was the inclusion of these tests in the assessment of women with cytologic atypia and women treated for cervical intraepithelial neoplasia (CIN). Testing for HPV is recommended in an organized screening scenario to identify women with precursor lesions or asymptomatic cervical cancer older than 30 years of age, and it can be performed every 5 years. It also has value after the cytology showing atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSILs) as a triage test for colposcopy, in the investigation of other cytological alterations when no abnormal findings are observed at colposcopy, seeking to exclude disease, or, further, after treatment of high-grade cervical intraepithelial neoplasia, to rule out residual disease.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2018;40(6):360-368
Evidence-based clinical guidelines ensure best practice protocols are available in health care. There is a widespread use of human papillomavirus deoxyribonucleic acid (HPVDNA) tests in Brazil, regardless of the lack of official guidelines. On behalf of the Brazilian Association for the Lower Genital Tract Pathology and Colposcopy (ABPTGIC, in the Portuguese acronym), a team of reviewers searched for published evidence and developed a set of recommendations for the use of HPV-DNA tests in cervical cancer screening in Brazil. The product of this process was debated and consensus was sought by the participants. One concern of the authors was the inclusion of these tests in the assessment of women with cytologic atypia and women treated for cervical intraepithelial neoplasia (CIN). Testing for HPV is recommended in an organized screening scenario to identify women with precursor lesions or asymptomatic cervical cancer older than 30 years of age, and it can be performed every 5 years. It also has value after the cytology showing atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSILs) as a triage test for colposcopy, in the investigation of other cytological alterations when no abnormal findings are observed at colposcopy, seeking to exclude disease, or, further, after treatment of high-grade cervical intraepithelial neoplasia, to rule out residual disease.
